Medical Scientist Training Program, Emory University School of Medicine, Atlanta, GA, USA.
Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA.
Nat Rev Gastroenterol Hepatol. 2020 Oct;17(10):597-617. doi: 10.1038/s41575-020-0331-7. Epub 2020 Jul 24.
Inflammatory bowel disease (IBD) affects 6.8 million people globally. A variety of factors have been implicated in IBD pathogenesis, including host genetics, immune dysregulation and gut microbiota alterations. Emerging evidence implicates intestinal epithelial glycosylation as an underappreciated process that interfaces with these three factors. IBD is associated with increased expression of truncated O-glycans as well as altered expression of terminal glycan structures. IBD genes, glycosyltransferase mislocalization, altered glycosyltransferase and glycosidase expression and dysbiosis drive changes in the glycome. These glycan changes disrupt the mucus layer, glycan-lectin interactions, host-microorganism interactions and mucosal immunity, and ultimately contribute to IBD pathogenesis. Epithelial glycans are especially critical in regulating the gut microbiota through providing bacterial ligands and nutrients and ultimately determining the spatial organization of the gut microbiota. In this Review, we discuss the regulation of intestinal epithelial glycosylation, altered epithelial glycosylation in IBD and mechanisms for how these alterations contribute to disease pathobiology. We hope that this Review provides a foundation for future studies on IBD glycosylation and the emergence of glycan-inspired therapies for IBD.
炎症性肠病(IBD)影响全球 680 万人。多种因素与 IBD 的发病机制有关,包括宿主遗传学、免疫失调和肠道微生物群的改变。新出现的证据表明,肠道上皮细胞糖基化是一个被低估的过程,它与这三个因素有关。IBD 与截短的 O-聚糖表达增加以及末端聚糖结构表达改变有关。IBD 基因、糖基转移酶定位错误、糖基转移酶和糖苷酶表达改变以及菌群失调导致糖组发生变化。这些聚糖变化破坏了黏液层、糖-凝集素相互作用、宿主-微生物相互作用和黏膜免疫,最终导致 IBD 的发病机制。上皮聚糖在通过提供细菌配体和营养物质来调节肠道微生物群方面尤为重要,并最终决定肠道微生物群的空间组织。在这篇综述中,我们讨论了肠道上皮细胞糖基化的调节、IBD 中上皮细胞糖基化的改变以及这些改变如何导致疾病发病机制的机制。我们希望这篇综述为未来关于 IBD 糖基化的研究以及基于聚糖的 IBD 治疗方法的出现提供基础。